BioinvestGPT

BioinvestGPT ApS · Research use only

NCT06493578 (VYN201 in Non-segmental Vitiligo): BVCT ex-ante prediction vs. reported outcome

On 27 Mar 2025, BioinvestGPT's BVCT predicted technical failure and commercial failure for this trial. The 30 Jul 2025 readout is classified on the dashboard as True Negative (TN), a correct prediction. Recorded clinical-benefit conclusion: statistically insignificant and commercially insufficient.

Clinical Trial

NCTID
NCT06493578
Drug Name
VYN201 (repibresib)
Drug MoA
BET inhibitor
Drug Modality
small molecule
Drug Class
First-In-Class
Therapeutic Area
Skin and Connective Tissue Diseases
Indication
Non-segmental Vitiligo
Human Patients
200
Sponsor
Vyne Therapeutics
Phase
Phase 2

Prediction of , index 1944

Prospective Prediction
Prediction Index
1944
Prediction Date
Commercial Prediction
FAILURE (commercially insufficient clinical benefit in F-VASI50/T-VASI50 inferior to baricitinib/ruxolitinib/upadacitinib)
Technical Prediction
FAILURE (statistically maybe significant yet very weak clinical benefit in F-VASI50/T-VASI50 compared with placebo)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
125 days in advance
Readout Data Interpretation
repibresib failed to achieve the primary endpoint in F-VASI50 at week 24
Press Release
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically insignificant and commercially insufficient
Prediction Classification
True Negative (TN)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
A Randomized, Double-Blind, Vehicle-Controlled Phase 2b Trial Evaluating the Efficacy, Safety & Pharmacokinetics of VYN201 Gel in the Treatment of Non Segmental Vitiligo
Phase
Phase 2
Status
Terminated
Enrollment
205
Lead sponsor
Vyne Therapeutics Inc.
Conditions
Non-segmental Vitiligo
Interventions
DRUG: VYN201 Gel; DRUG: Vehicle Gel
Design
Randomized · Parallel · Quadruple
Primary purpose
Treatment
Start
2024-06-04
Primary completion
2025-07-10
Completion
2025-09-30
Primary outcomes
  • To evaluate the efficacy of VYN201 compared to vehicle at Week 24 in subjects with NSV. (Week 24)

NCT06493578 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials